Eli Lilly (LLY) partners with SanegeneBio in a deal worth up to $1.2B to develop and commercialize RNAi therapeutics for ...

Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy. Learn why LLY ...

People look to pickup truck engines for consistent power and long term durability. These ones in particular are among the all-time most reliable engines.

When performing onstage, Dania Hallak, a singer and songwriter, sometimes found she couldn’t hit lower notes. Her vocal coach suggested it was performance anxiety. Hallak saw her doctor, who ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the ...

Doctors are reassessing decades of standard treatment for patients who have had heart attacks after new research shows beta-blockers may be anywhere from useless to harmful in certain cases. The ...

Eli Lilly's stock price has been rangebound for most of the past two years. Sales of existing and upcoming diabetes and obesity treatments are likely to continue growing at a rapid clip. While Lilly's ...

Inevitably, whenever there is a discussion on the internet about how YouTube (or any other website) is choked with ads, someone will say, "Just use an ad blocker." The name seems to say it all. An ad ...

Eli Lilly and Company (NYSE:LLY) is among the 10 Best Money Making Stocks to Invest In. According to a U.S. registry of clinical trials, the firm has halted an experimental drug study designed to stop ...

With a strong profitability outlook, Eli Lilly and Company (NYSE:LLY) secures a spot on our list of the 14 Stocks That Will Double in the Next 5 Years. On September 26, 2025, Eli Lilly and Company ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was ...